Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Susanne R Bruekner und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biochemistry, Netherlands Cancer Institute and Oncode Institute, 1066 CX Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: DNA Mismatch Repair, DNA Repair, MutS Homolog 2 Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dutch Research Council, European Commission, Dutch Cancer Society.
Abstract (Originalsprache)
The DNA mismatch repair protein MutSα recognizes wrongly incorporated DNA bases and initiates their correction during DNA replication. Dysfunctions in mismatch repair lead to a predisposition to cancer. Here, we study the homozygous mutation V63E in MSH2 that was found in the germline of a patient with suspected constitutional mismatch repair deficiency syndrome who developed colorectal cancer before the age of 30. Characterization of the mutant in mouse models, as well as slippage and repair assays, shows a mildly pathogenic phenotype. Using cryogenic electron microscopy and surface plasmon resonance, we explored the mechanistic effect of this mutation on MutSα function. We discovered that V63E disrupts a previously unappreciated interface between the mismatch binding domains (MBDs) of MSH2 and MSH6 and leads to reduced DNA binding. Our research identifies this interface as a ‘safety lock’ that ensures high-affinity DNA binding to increase replication fidelity. Our mechanistic model explains the hypomorphic phenotype of the V63E patient mutation and other variants in the MBD interface.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Biochemistry, Netherlands Cancer Institute and Oncode Institute, 1066 CX Amsterdam, The Netherlands.
- Division of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066CX Amsterdam, The Netherlands.
- Structural Biochemistry, Bijvoet Centre for Biomolecular Research, Utrecht University, 3584CH Utrecht, The Netherlands.
- Department of Human Genetics, Leiden University Medical Center, PO Box 9600 2300RC Leiden, The Netherlands.
- Department of Pathology, Erasmus Medical Center, PO Box 2040 3000CA Rotterdam, The Netherlands.
- Sultan Qaboos Comprehensive Cancer Care and Research Center, PO Box 787, 117 Muscat, Oman.
ORCID-Profile: Niels de Wind, Hein Te Riele, Titia K Sixma
Förderung
- Dutch Research Council
- European Commission
- Dutch Cancer Society
- European Commision
- Netherlands Cancer Institute
Zitieren
APA
Bruekner, S. R., Pieters, W., Fish, A., Liaci, A. M., Scheffers, S., Rayner, E., Kaldenbach, D., Drost, L., Dekker, M., van Hees-Stuivenberg, S., Delzenne-Goette, E., de Konink, C., Houlleberghs, H., Dubbink, H. J., AlSaegh, A., de Wind, N., Förster, F., Te Riele, H., & Sixma, T. K. (2023). Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad015
Vancouver
Bruekner SR, Pieters W, Fish A, Liaci AM, Scheffers S, Rayner E, et al. Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad015
BibTeX
@article{Bruekner2023,
author = {Bruekner, Susanne R and Pieters, Wietske and Fish, Alexander and Liaci, A Manuel and Scheffers, Serge and Rayner, Emily and Kaldenbach, Daphne and Drost, Lisa and Dekker, Marleen and van Hees-Stuivenberg, Sandrine and Delzenne-Goette, Elly and de Konink, Charlotte and Houlleberghs, Hellen and Dubbink, Hendrikus Jan and AlSaegh, Abeer and de Wind, Niels and Förster, Friedrich and Te Riele, Hein and Sixma, Titia K},
title = {Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad015}
}
EUVIMED